1. Home
  2. ALLR vs ATCH Comparison

ALLR vs ATCH Comparison

Compare ALLR & ATCH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Allarity Therapeutics Inc.

ALLR

Allarity Therapeutics Inc.

HOLD

Current Price

$1.30

Market Cap

25.6M

Sector

Health Care

ML Signal

HOLD

Logo AtlasClear Holdings Inc.

ATCH

AtlasClear Holdings Inc.

HOLD

Current Price

$0.19

Market Cap

29.6M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
ALLR
ATCH
Founded
2004
2022
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
25.6M
29.6M
IPO Year
2021
2024

Fundamental Metrics

Financial Performance
Metric
ALLR
ATCH
Price
$1.30
$0.19
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
1
Target Price
$9.75
$1.00
AVG Volume (30 Days)
145.6K
1.4M
Earning Date
05-15-2026
05-15-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.05
Revenue
$320,000.00
N/A
Revenue This Year
N/A
$84.47
Revenue Next Year
N/A
$39.32
P/E Ratio
N/A
$3.88
Revenue Growth
N/A
N/A
52 Week Low
$0.77
$0.14
52 Week High
$2.35
$1.92

Technical Indicators

Market Signals
Indicator
ALLR
ATCH
Relative Strength Index (RSI) 41.98 41.77
Support Level $1.28 $0.19
Resistance Level $1.43 $0.22
Average True Range (ATR) 0.12 0.01
MACD -0.01 0.00
Stochastic Oscillator 19.41 25.65

Price Performance

Historical Comparison
ALLR
ATCH

About ALLR Allarity Therapeutics Inc.

Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States. It is focused on the clinical development of its lead program: Stenoparib, which is being co-developed with a drug specific DRP companion diagnostic.

About ATCH AtlasClear Holdings Inc.

AtlasClear Holdings Inc is a fintech company. Its goal is to build a cutting-edge technology-enabled financial services firm that would create a more efficient platform for trading, clearing, settlement, and banking of evolving and financial products with a focus on financial services firms. It is a fintech-driven business-to-business platform that expects to power innovation in fintech, investing, and trading. The company believes it is positioned to provide a modern, mission-critical suite of solutions to its clients, enabling them to reduce their transaction costs and compete more effectively in their businesses.

Share on Social Networks: